**EQUITY RESEARCH - RESULTS FLASH** 

THAILAND / HEALTH CARE SERVICES







## **BDMS TB**

TARGET PRICE

**UP/DOWNSIDE** 

TP vs CONSENSUS

CLOSE



THB31.50

THB22.90

+37.6%

+5.6%

## 2Q25 results at first glance

## ้กำไรปกติ 2Q25 เติบโตปานกลาง (+5% y-y) เป็นไปตามที่เราและตลาดคาด

## **Highlights**

BDMS รายงานกำไรปกติ 2Q25 ที่ 3,490 ล้านบาท (-20% q-q, +5% y-y) สอดคล้องกับ ประมาณการของเราและ Bloomberg consensus การลดลง q-q เป็นผลจากฤดูกาล ขณะที่การเติบโต y-y มาจากรายได้ผู้ป่วยที่สูงขึ้นและอัตรา EBITDA margin ที่ยังคง

**BANGKOK DUSIT MEDICAL SERVICES** 


- รายได้รวมอยู่ที่ 27,130 ล้านบาท ลดลง 5% q-q จากช่วงสิ้นสุดไฮซีซันของการเดินทาง จากชาวต่างชาติ แต่ยังเพิ่มขึ้น 4% y-y จากการเติบโตของรายได้ทั้งผู้ป่วยไทยและ ต่างชาติที่ 3% และ 8% y-y ตามลำดับ แม้ว่าจะมีจำนวนผู้ป่วยจากกัมพูชาและจีนลดลง และความเชื่อมั่นผู้บริโภคในประเทศอ่อนตัว ทำให้การเติบโตในเดือนมิถุนายนชะลอลง เมื่อเทียบกับเมษายน–พฤษภาคม
- สัดส่วนรายได้จากผู้ป่วยในประเทศและต่างประเทศอยู่ที่ 72% และ 28% ตามลำดับ ส่วน รายได้ผู้ป่วยนอกและผู้ป่วยในอยู่ที่ 50%–50% ในไตรมาสนี้ อัตรา EBITDA margin ปรับตัวดีขึ้น 1ppt y-y จากความเข้มข้นของรายได้และการบริหารต้นทุนที่มีประสิทธิภาพ

#### **Outlook**

- กำไรปกติ 1H25 อยู่ที่ 7,840 ล้านบาท (+6% y-y) คิดเป็น 47% ของประมาณการทั้งปี 2025 ของเรา สอดคล้องกับค่าเฉลี่ยย้อนหลัง 3 ปี เราคาดว่ากำไรครึ่งหลังปี 2H25 ของ BDMS จะเติบโตทั้ง h-h และ y-y โดยกำไร 3Q25 คาดว่าจะขยายตัวทั้ง q-q และ y-y
- คาดรายได้จากผู้ป่วยชาวไทยฟื้นตัว q-q ใน 3Q25 ซึ่งเป็นไฮซีซันของบริการทาง การแพทย์ ขณะที่จำนวนผู้ป่วยต่างชาติก็น่าจะเพิ่มขึ้นในช่วงครึ่งหลังของปี สนับสนุนทั้ง การดำเนินงานของโรงพยาบาลในกรุงเทพฯ และต่างจังหวัด
- เรายังคงประมาณการเดิม โดยคาดว่ากำไรหลักจะเติบโตอย่างต่อเนื่องและเร่งตัวที่ 4%/7%/9% ในปี 2025/26/27 ราคาหุ้น BDMS ปัจจุบันนับว่ายังคงน่าสนใจในเชิงการ ประเมินมูลค่า โดยซื้อขายที่ 21.8x 2025E P/E หรือ -2.0SD จากค่าเฉลี่ยย้อนหลัง 10 ปี

## **KEY STOCK DATA**

YE Dec (THB m)	2024	2025E	2026E	2027E
Revenue	109,351	114,131	121,589	128,930
Net profit	15,987	16,682	17,912	19,486
EPS (THB)	1.01	1.05	1.13	1.23
vs Consensus (%)	-	(0.1)	0.4	1.9
EBITDA	26,584	27,860	29,924	32,053
Recurring net profit	15,987	16,682	17,912	19,486
Core EPS (THB)	1.01	1.05	1.13	1.23
EPS growth (%)	11.2	4.3	7.4	8.8
Core P/E (x)	22.8	21.8	20.3	18.7
Dividend yield (%)	2.8	3.3	3.3	3.4
EV/EBITDA (x)	14.2	13.4	12.3	11.3
Price/book (x)	3.6	3.5	3.3	3.1
Net debt/Equity (%)	9.3	4.7	(0.5)	(6.8)
ROE (%)	16.4	16.3	16.6	17.1



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	14.5	(5.0)	(17.5)
Relative to country (%)	0.5	(9.7)	(16.2)
Mkt cap (USD m)			11,282
3m avg. daily turnover (USD m)			31.3
Free float (%)			84
Major shareholder		Thai N\	/DR (11%)
12m high/low (THB)		3	1.25/19.80
Issued shares (m)			15,892.00

Sources: Bloomberg consensus; FSSIA estimates



Vatcharut Vacharawongsith

Fundamental Investment Analyst on Securities; License no. 018301 vatcharut.v@fssia.com, +66 2646 9969

Exhibit 1: BDMS - 2Q25 results summary

	2Q24	3Q24	4Q24	1Q25	2Q25	Cha	nge	2024	2025E	Change
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %)				
Sales	26,058	28,536	27,828	28,453	27,134	(5)	4	109,351	114,131	4
- Hospital revenue	24,694	27,108	26,347	27,078	25,699	(5)	4	103,675	108,605	5
- Other revenue	1,364	1,428	1,481	1,375	1,434	4	5	5,676	5,526	(3)
COGS (incl depreciation)	(16,664)	(17,634)	(17,037)	(17,686)	(17,335)	(2)	4	(68,071)	(71,172)	5
Gross profit	9,394	10,901	10,791	10,767	9,798	(9)	4	41,280	42,958	4
SG&A	(5,146)	(5,313)	(5,476)	(5,153)	(5,323)	3	3	(20,828)	(21,624)	4
Operating profit <sup>1)</sup>	4,248	5,588	5,315	5,614	4,475	(20)	5	20,452	21,334	4
Net other income	23	20	9	9	28	195	20	62	68	10
Interest income	47	40	39	31	34	7	(29)	175	160	(8)
Interest expense	(111)	(102)	(108)	(97)	(96)	(1)	(13)	(433)	(400)	(8)
Pretax profit	4,208	5,546	5,255	5,557	4,440	(20)	6	20,255	21,162	4
Income Tax	(756)	(1,153)	(841)	(1,081)	(836)	(23)	11	(3,792)	(3,978)	5
Associates	14	24	25	19	13	(28)	(5)	76	84	10
Minority interest	(131)	(171)	(107)	(149)	(128)	(14)	(3)	(552)	(585)	6
Core profit	3,335	4,246	4,333	4,346	3,490	(20)	5	15,987	16,682	4
Extraordinaries, GW & FX								0	0	
Reported net profit	3,335	4,246	4,333	4,346	3,490	(20)	5	15,987	16,682	4
Outstanding shares (m)	15,892	15,892	15,892	15,892	15,892	0	0	15,892	15,892	0
Core EPS (THB)	0.21	0.27	0.27	0.27	0.22	(20)	5	1.01	1.05	4
EPS (THB)	0.21	0.27	0.27	0.27	0.22	(20)	5	1.01	1.05	4
COGS Excl depreciation	15,161	16,087	15,433	16,064	15,676	(2)	3	61,939	64,646	4
Depreciation	1,503	1,548	1,605	1,622	1,659	2	10	6,132	6,526	6
EBITDA <sup>2)</sup>	5,751	7,136	6,919	7,236	6,134	(15)	7	26,584	27,860	5
Key ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(ppt)
Gross margin	36	38	39	38	36	(2)	0	38	38	(0)
SG&A/Revenue	20	19	20	18	20	2	(0)	19	19	(0)
EBITDA margin	22	25	25	25	23	(3)	1	24	24	0
Net profit margin	13	15	16	15	13	(2)	0	15	15	(0)
Operating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	9	6	6	4	6					
IPD revenue growth y-y	5	6	2	8	2					
Thai revenue growth y-y	5	6	2	4	3					
International revenue growth y-y	11	8	10	11	8					

Note: 1) Gross profit calculated by revenue – COGS including depreciation; 2) EBITDA calculated by operating profit + operating income – depreciation Sources: BDMS; FSSIA estimates

## **Financial Statements**

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Revenue	102,110	109,351	114,131	121,589	128,930
Cost of goods sold	(63,412)	(68,071)	(71,172)	(75,513)	(79,695)
Gross profit	38,698	41,280	42,958	46,076	49,235
Other operating income	-	-	-	-	-
Operating costs	(19,806)	(20,828)	(21,624)	(22,916)	(24,171)
Operating EBITDA	24,740	26,584	27,860	29,924	32,053
Depreciation	(5,848)	(6,132)	(6,526)	(6,763)	(6,988)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	18,892	20,452	21,334	23,160	25,065
Net financing costs	(373)	(259)	(240)	(170)	(63)
Associates	89	76	84	92	101
Recurring non-operating income	133	138	151	167	183
Non-recurring items	0	0	0	0	0
Profit before tax	18,652	20,331	21,246	23,157	25,185
Tax	(3,755)	(3,792)	(3,978)	(4,613)	(5,017)
Profit after tax	14,897	16,539	17,267	18,544	20,168
Minority interests	(522)	(552)	(585)	(632)	(683)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	14,375	15,987	16,682	17,912	19,486
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	14,375	15,987	16,682	17,912	19,486
Per share (THB)					
Recurring EPS *	0.90	1.01	1.05	1.13	1.23
Reported EPS	0.90	1.01	1.05	1.13	1.23
DPS	0.65	0.65	0.75	0.76	0.79
Diluted shares (used to calculate per share data)	15,892	15,892	15,892	15,892	15,892
Growth					
Revenue (%)	9.8	7.1	4.4	6.5	6.0
Operating EBITDA (%)	7.9	7.5	4.8	7.4	7.1
Operating EBIT (%)	11.2	8.3	4.3	8.6	8.2
Recurring EPS (%)	14.0	11.2	4.3	7.4	8.8
Reported EPS (%)	14.0	11.2	4.3	7.4	8.8
Operating performance					
Gross margin inc. depreciation (%)	37.9	37.8	37.6	37.9	38.2
Gross margin exc. depreciation (%)	43.6	43.4	43.4	43.5	43.6
Operating EBITDA margin (%)	24.2	24.3	24.4	24.6	24.9
Operating EBIT margin (%)	18.5	18.7	18.7	19.0	19.4
Net margin (%)	14.1	14.6	14.6	14.7	15.1
Effective tax rate (%)	20.2	18.7	18.8	20.0	20.0
Dividend payout on recurring profit (%)	71.9	64.7	71.4	67.5	64.3
Interest cover (X)	51.0	79.6	89.5	136.9	401.5
Inventory days	14.7	14.8	15.0	14.9	14.9
Debtor days	39.4	39.7	39.2	36.8	34.7
Creditor days	41.5	44.2	46.8	46.4	46.5
Operating ROIC (%)	16.1	16.8	16.9	17.9	19.3
ROIC (%)	13.1	13.7	13.8	14.7	15.9
ROE (%)	15.5	16.4	16.3	16.6	17.1
ROA (%)	10.7	11.4	11.4	11.8	12.2
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2023	2024	2025E	2026E	2027E
Thai patient revenue	70,866	74,646	76,837	80,842	85,797
International patient revenue	26,211	29,029	31,768	34,944	37,041
•	5,034	5,676	5,526	5,802	6,092

Sources: Bangkok Dusit Medical Services; FSSIA estimates

## **Financial Statements**

Bangkok Dusit Medical Services

Cash Flow (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Recurring net profit	14,375	15,987	16,682	17,912	19,486
Depreciation	5,848	6,132	6,526	6,763	6,988
Associates & minorities	-	-	-	-	-
Other non-cash items	1,203	(195)	585	632	683
Change in working capital	161	689	633	976	954
Cash flow from operations	21,588	22,613	24,426	26,283	28,110
Capex - maintenance	(11,612)	(12,917)	(7,989)	(8,511)	(7,736)
Capex - new investment	-	-	-	-	-
Net acquisitions & disposals	(290)	(353)	0	0	0
Other investments (net)	<u>-</u>		-		<del>-</del>
Cash flow from investing	(11,902)	(13,270)	(7,989)	(8,511)	(7,736)
Dividends paid	(10,343)	(10,342)	(11,919)	(12,094)	(12,538)
Equity finance	0	0	0	0	0
Debt finance	(5,460)	224	(3,000)	(500)	(500)
Other financing cash flows	612	(2)	0	0	0
Cash flow from financing	(15,190)	(10,120)	(14,919)	(12,594)	(13,038)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0 <b>0</b>	0 <b>0</b>	0 <b>0</b>	0 <b>0</b>	0 <b>0</b>
Net other adjustments					
Movement in cash	(5,505)	(777)	1,517	5,178	7,336
Free cash flow to firm (FCFF)	10,232.29 4,838.23	9,776.55 9,565.32	16,836.89	18,130.96	20,721.40
Free cash flow to equity (FCFE)	4,030.23	9,565.32	13,436.48	17,272.11	19,874.43
Per share (THB)	0.04	0.00	4.00	4 4 4	4.00
FCFF per share	0.64	0.62	1.06	1.14	1.30
FCFE per share Recurring cash flow per share	0.30 1.35	0.60 1.38	0.85 1.50	1.09 1.59	1.25 1.71
Balance Sheet (THB m) Year Ending Dec	2023	2024	2025E	2026E	2027E
Tangible fixed assets (gross)	165,315	174,246	182,235	190,746	198,482
Less: Accumulated depreciation	(67,642)	(69,788)	(76,313)	(83,077)	(90,065)
Tangible fixed assets (net)	97,673	104,458	105,921	107,669	108,417
Intangible fixed assets (net)	19,376	19,813	19,813	19,813	19,813
Long-term financial assets	- 0.070	-	-		- 0.000
nvest. in associates & subsidiaries	2,276	2,629	2,629	2,629	2,629
Cash & equivalents	9,467	8,690	10,208	15,385	22,722
A/C receivable	11,558	12,246	12,246	12,246	12,246
Inventories	2,420	2,603	2,717	2,890	3,056
Other current assets	101	120	125	133	141
Current assets Other assets	<b>23,545</b> 726	<b>23,659</b> 955	<b>25,296</b> 955	<b>30,654</b> 955	38,165
Total assets	143,596	151,514	1 <b>54,614</b>	161,720	955 <b>169,978</b>
Common equity	95,242	· ·	104,799	110,617	117,564
Minorities etc.	3,630	100,037 3,890	4,475	5,107	5,790
Total shareholders' equity	98,872	103,927	109,275	115,724	123,354
Long term debt	18,134	15,858	15,358	14,858	14,358
Other long-term liabilities	10,973	12,034	12,034	12,034	12,034
Long-term liabilities	29,107	27,892	27,392	26,892	26,392
A/C payable	6,901	8,113	8,468	9,005	9,524
Short term debt	0,301	2,500	0,400	0,000	0,324
Other current liabilities	8,715	9,082	9,479	10,098	10,708
Current liabilities	15,616	19,695	17,947	19,104	20,232
Total liabilities and shareholders' equity	143,596	151,514	154,614	161,720	169,978
Net working capital	(1,538)	(2,226)	(2,859)	(3,835)	(4,789)
nvested capital	118,513	125,628	126,459	127,231	127,025
Includes convertibles and preferred stock which is be		,	,	,	,,
Per share (THB)					
Book value per share	5.99	6.29	6.59	6.96	7.40
Fangible book value per share	4.77	5.05	5.35	5.71	6.15
Financial strength					
Net debt/equity (%)	8.8	9.3	4.7	(0.5)	(6.8)
Net debt/total assets (%)	6.0	6.4	3.3	(0.3)	(4.9)
Current ratio (x)	1.5	1.2	1.4	1.6	1.9
CF interest cover (x)	14.0	38.0	57.0	102.4	317.1
Valuation	2023	2024	2025E	2026E	2027E
Recurring P/E (x) *	25.3	22.8	21.8	20.3	18.7
Recurring P/E @ target price (x) *	34.8	31.3	30.0	27.9	25.7
Reported P/E (x)	25.3	22.8	21.8	20.3	18.7
Dividend yield (%)	2.8	2.8	3.3	3.3	3.4
Price/book (x)	3.8	3.6	3.5	3.3	3.1
Price/book (x)	4.8	4.5	4.3	4.0	3.7
EV/EBITDA (x) **	15.2	14.2	13.4	12.3	11.3
	10.2	17.4			
	20.7	19.3	18.3	16.9	15.5
EV/EBITDA (x)  EV/EBITDA @ target price (x) **  EV/invested capital (x)	20.7 3.2	19.3 3.0	18.3 3.0	16.9 2.9	15.5 2.8

Sources: Bangkok Dusit Medical Services; FSSIA estimates

# **Bangkok Dusit Medical Serv (BDMS TB)**

FSSIA ESG rating

★ ★ ★ ★

## **Exhibit 2: FSSIA ESG score implication**

74.00 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA			Domestic	ratings					Glo	bal ratings	;		Bloomberg	
	ESG score	DJSI	SET ESG	SET ESG Rating	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	BB	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	3	4	9	35	9	34
GHG scope 2 location-based	_	_	91	92	98	94	96	209
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	_	_	_	_	_	_	_	5
Electricity used	_	_	143	145	152	147	192	417
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

**Exhibit 5: ESG score by Bloomberg** (cont.)

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	No
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Hazardous waste	_	_	1	2	2	2	3	5
Total waste	_	_	6	7	7	5	9	13
Waste recycled	_	_	0	1	1	0	1	2
Waste sent to landfills	_	_	_	_	_	_	3	5
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Water policy	No	No	No	Yes	Yes	Yes	Yes	Yes
Water consumption	_	_	354	358	388	332	472	754
Social								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Policy against child labor	No	No	No	No	No	Yes	Yes	Yes
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Yes
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Gender pay gap breakout	No	No	No	No	No	No	No	No
Pct women in workforce	_	_	82	82	82	82	83	83
Pct disabled in workforce	_	_	_	_	_	_	_	_
Business ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Lost time incident rate - employees	_	_	0	0	0	0	0	1
Total recordable incident rate - employees	_	_	2	2	2	1	1	1
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
Fair remuneration policy	No	No	No	No	No	No	No	No
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,495
Employee turnover pct	-	_	18	19	19	17	16	20
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,320
Social supply chain management	No	No	No	No	Yes	Yes	Yes	Yes
Governance	110	110	140	110	100	100	100	100
Board size	15	14	13	14	14	16	18	17
No. of independent directors (ID)	7	6	6	6	6	7	7	7
No. of women on board	2	1	1	1	1	2	2	2
No. of non-executive directors on board	9	7	6	8	9	9	9	9
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Yes
No. of board meetings for the year	13	13	14	12	13	12	12	12
	95	94	98	97	98	98	97	100
Board meeting attendance pct Board duration (years)	3	3	3	3	3	3	3	3
Director share ownership guidelines	No No	No	No	No	No	No	No	No.
. 5								
Age of the joinest director	45	42	43	44	45 97	46	47	48
Age of the oldest director	83	84	85 <b>5</b>	86	87	88	89	90
No. of executives / company managers	4	5	5	5	6	7	5	5
No. of female executives			1	2	1	2	2	2
Executive share ownership guidelines	No	No	No	No	No	No	No	No
Size of audit committee	3	3	3	3	3	3	3	3
No. of ID on audit committee	3	3	3	3	3	3	3	3
Audit committee meetings	10	9	10	7	10	6	6	6
Audit meeting attendance %	100	100	100	100	97	100	100	100
Size of compensation committee	4	4	4	4	4	3	3	3
No. of ID on compensation committee	3	3	3	2	2	2	2	2
No. of compensation committee meetings	3	1	4	4	3	4	4	3
Compensation meeting attendance %	100	100	100	100	100	100	100	100
Size of nomination committee	4	4	4	4	4	3	3	3
No. of nomination committee meetings	3	1	4	4	3	4	4	3
Nomination meeting attendance %	100	100	100	100	100	100	100	100
Sustainability governance								
Verification type	No	No	No	No	No	No	No	No

Sources: Bloomberg; FSSIA's compilation

## **Disclaimer for ESG scoring**

ESG score	Methodolog	у			Rating				
The Dow Jones Sustainability Indices (DJSI) By S&P Global	process bas from the anr Only the top inclusion.	ed on the com nual S&P Glob -ranked comp	transparent, rules-based panies' Total Sustainabili al Corporate Sustainabilit anies within each industry	ity Scores resulting y Assessment (CSA). y are selected for	Sustainability A ESG Score of le scoring compar selected from the	ssessment (C ess than 45% ny are disqual ne Eligible Un		ompanies with al ESG Score uents of the D	an S&P Globa of the highest JSI indices are
SET ESG Ratings List (SETESG) by The Stock Exchange of Thailand (SET)	managing be Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tr must pass the ar trading of th shareholders come key disque ependent direct related to CG	unsibility in Environmental ansparency in Governance preemptive criteria, with the board members and explain and combined holding mulalifying criteria include: 1 stors and free float violation, social & environmental internings in red for > 3 year	ce, updated annually. two crucial conditions: tecutives; and 2) free nust be >15% of paid- ) CG score of below in; 3) executives' impacts; 4) equity in	minimum of 500 during the assenature of the re SETESG Index 1) market capit: liquidity >0.5% SETTHSI Index	% for each ind ssment year. levant industr is extended falization > TH of paid-up cap is a market of	iclusion, verified licator, unless the The scoring will by and materiality. From the SET ES B5b (~USD150b) bital for at least 9 apitalisation-weig, and no cap for i	e company is coe fairly weigh G Ratings cor (; 2) free float out of 12 mor ghted index, c	a part of DJSI ated against the against the apanies whose >20%; and 3) at the ap 5%
CG Score by Thai Institute of Directors Association (Thai IOD)	annually by Thailand (St	the Thai IOD,	h in sustainable developm with support from the Sto ts are from the perspectiv s.	ck Exchange of	Good (80-89), 3 and not rated for equitable treatm	B for Good (70 or scores belo nent of shareh 5%); 4) disclo	ories: 5 for Excell 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 sure & transpare	60-69), 1 for P s include: 1) th 5% combined	ass (60-69), the rights; 2) and (); 3) the role of
AGM level By Thai Investors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiabilit	e incorporated and sufficiently e CG compon r AGM proced and after the in sufficient informate e second assess y; and 3) openne	which shareholders' rights into business operations y disclosed. All form imponents to be evaluated annuars before the meeting (meeting (10%). (The first as tion for voting; and 2) facilitations: I) the ease of attending mess for Q&A. The third involves es, resolutions and voting res	s and information is rtant elements of two ually. The assessment 45%), at the meeting ssesses 1) advance ing how voting rights can be eetings; 2) transparency is the meeting minutes that			four categories: (80-89), and not		
Thai CAC By Thai Private Sector Collective Action Against Corruption (CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key contree Certification leciding to become Intent to kick officialist ass	Checklist include corruption of the monitoring and is and the monitoring and is a CAC certified member stated in 18-month deadline to subsessment, in place of policy and ablishment of whistleblowing of the stakeholders.)	art by submitting a mit the CAC Checklist for a control, training of	passed Checkli	st will move for se members a	ed by a committe or granting certific re twelve highly r chievements.	cation by the 0	CAC Council
Morningstar Sustainalytics	based on an risk is unma regulatory filin	assessment on aged. Source gs, news and other	sk rating provides an over of how much of a compan is to be reviewed include corpor her media, NGO reports/webs k, ESG controversies, issuer t	ny's exposure to ESG orate publications and orites, multi-sector			score is the sum higher ESG risk Medium		ed risk. The
		uality & peer rev		eedback on drait LSG	0-10	10-20	20-30	30-40	40+
ESG Book	positioned to the principle helps explai over-weighti	o outperform o of financial m n future risk-a	sustainable companies the over the long term. The me ateriality including information dijusted performance. Mat the higher materiality and really basis.	ethodology considers ation that significantly eriality is applied by	The total ESG s	score is calcul ateriality-base	ated as a weighted weights. The s	ed sum of the core is scaled	features
MSCI			measure a company's ma						nethodology to
	AAA	8.571-10.00	0	landing to industry in my		:fit FCC =:	alsa and annauturitia		
	AA	7.143-8.570	Leader:	leading its industry in ma	anaging tile most si	giiiiloanii E3G II	σκο απα υρρυπαππιέ		
	Α	5.714-7.142	2						
	BBB	4.286-5.713	Average:	a mixed or unexceptional industry peers	al track record of ma	anaging the mos	t significant ESG ris	sks and opportur	nities relative to
	ВВ	2.857-4.285	5	, .					
	В	1.429-2.856	Laggard:	lagging its industry base	d on its high evacs	ure and failure +	n manage significan	ıt FSG riske	
	ccc	0.000-1.428		lagging its industry base	a on no night expus	a.o ana milite l	nanage signilican	113/13	
Moody's ESG solutions	believes tha	t a company ir	gree to which companies to tegrating ESG factors into the result of shareholders over the results.	o its business model and					
Refinitiv ESG rating	based on pu	blicly available	and objectively measure e and auditable data. The ta publicly. (Score ratings a	score ranges from 0 to 1	00 on relative E	SG performar	ice and insufficie	nt degree of ti	
S&P Global			re is a relative score mea in the same industry class				of ESG risks, opp	portunities, an	d impacts
Bloomberg	ESG Score		score is based on Bloon	ating the company's aggr nberg's view of ESG fina the weights are determin	ncial materiality.	The score is	a weighted gener	alized mean (	power mean)

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

#### **GENERAL DISCLAIMER**

## ANALYST(S) CERTIFICATION


### Vatcharut Vacharawongsith FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

### History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
06-Oct-2022 08-Jan-2023	BUY BUY	33.00 34.50	18-Jan-2024 10-Oct-2024	BUY BUY	35.00 36.50	03-Jul-2025	BUY	31.50

Vatcharut Vacharawongsith started covering this stock from 03-Jul-2025

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 22.90	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 13-Aug-2025 unless otherwise stated.

### RECOMMENDATION STRUCTURE

## Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

### **Industry Recommendations**

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.